MuSK Myasthenia Gravis
Neurology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Cabaletta BioMuSK-CAART
Clinical Trials (1)
Total enrollment: 7 patients across 1 trials
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Start: Nov 2022Est. completion: Jul 20257 patients
Phase 1Completed
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
8h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
9h ago
Director of Finance
CoMind
London, UK
9h ago
Electronics Engineering Manager
CoMind
London, UK
9h ago
Director of Information Technology
Zavation Medical Products
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space